細胞轉染市場規模、佔有率和成長分析：按轉染方法、最終用戶和地區分類－2026-2033年產業預測

2024年全球細胞轉染市場價值為24億美元，預計將從2025年的26.2億美元成長到2033年的53.4億美元。預測期（2026-2033年）的複合年成長率預計為9.3%。

包括學術界、工業界和臨床應用在內的各個領域對創新基因修飾工具的需求日益成長，推動了全球細胞轉染市場的發展。高效的核酸遞送對於功能基因組學以及細胞和基因療法的開發等領域的進步至關重要。隨著效率和擴充性變得至關重要，非病毒化學試劑正顯著轉向最佳化的電穿孔系統和病毒載體。此外，CAR-T療法等細胞和基因療法的日益普及也對可靠的轉染方法提出了更高的要求，迫使供應商持續提升其產品競爭力。人工智慧正在透過最佳化設計和工作流程，打造夥伴關係解決方案，從而改變這一領域。這些解決方案能夠提高可重複性，縮短開發週期，並促進生物製藥和生物技術生態系統內的合作。

全球細胞轉染市場促進因素

基因療法和核酸藥物研究的不斷深入，顯著提升了對高效細胞轉染解決方案的需求。研究人員在藥物發現和臨床前開發過程中，需要可靠的方法將遺傳物質導入各種細胞類型。這種科研趨勢促使實驗室和受託研究機構投資於檢驗的轉染試劑和平台，以簡化複雜的工作流程。為此，供應商正致力於拓展產品線並提升產品效能。因此，持續的研究活動推動了轉染領域的創新和商業化，從而增強了供應鏈，並提升了市場競爭力。

全球細胞轉染市場的限制因素

全球細胞轉染市場面臨許多限制因素，其中高品質轉染試劑、專用遞送系統和自動化平台成本高成本且波動較大。這些經濟壁壘尤其影響學術實驗室和小規模服務供應商，阻礙了他們採購必要材料的能力，並限制了市場滲透率。預算限制往往迫使研究人員選擇成熟的方法而非新興且昂貴的創新技術，從而抑制了對尖端產品的需求。此外，對成本的高度敏感性限制了常規應用所需的方法檢驗和最佳化投資，最終導致商業性化應用受限，並阻礙了供應商拓展產品線和探索細分市場機會。

全球細胞轉染市場趨勢

全球細胞轉染市場呈現顯著上升趨勢，這主要得益於單細胞應用中對精準、低毒性遞送方法日益成長的需求。研究人員正致力於開發先進的轉染技術，以促進下游體學工作流程所需的穩定表達，同時保持細胞活力。這一趨勢推動了擴充性、微創且與微流體平台相容的技術的發展，並促進了這些技術與單細胞定序和高內涵分析的融合。隨著供應商將可重複性和易整合性置於優先地位，細胞轉染正逐漸成為支持藥物發現、生物標記鑑定、治療方法開發和臨床應用等各個領域的關鍵基礎技術。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

市場考察

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場吸引力指數
• PESTEL 分析
• 監理情勢

全球細胞轉染市場規模：依轉染方法及複合年成長率分類（2026-2033 年）

• 電穿孔
• 脂質體
• 磷酸鈣法
• 病毒轉染
• 其他

全球細胞轉染市場規模：依最終用戶和複合年成長率分類（2026-2033 年）

• 學術機構
• 製藥公司
• 生技公司
• CRO（受託研究機構）

全球細胞轉染市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 2023-2025年營收年比比較

主要企業簡介

• Thermo Fisher Scientific, Inc.
• QIAGEN
• Lonza
• Promega Corporation
• Bio-Rad Laboratories Inc.
• Merck KGaA
• F. Hoffmann-La Roche Ltd.
• OriGene Technologies Inc.
• MaxCyte, Inc.
• POLYPLUS TRANSFECTION
• Agilent Technologies, Inc.
• Takara Bio Inc.
• GenScript Biotech Corporation
• ATCC
• Cellink
• EMD Millipore
• SignaGen Laboratories
• Mirus Bio LLC
• New England Biolabs, Inc.
• Cellecta, Inc.

結論與建議

Global Cell Transfection Market size was valued at USD 2.4 Billion in 2024 and is poised to grow from USD 2.62 Billion in 2025 to USD 5.34 Billion by 2033, growing at a CAGR of 9.3% during the forecast period (2026-2033).

The global cell transfection market is driven by an increasing demand for innovative gene-modification tools in various sectors, including academia, industry, and clinical applications. Efficient nucleic acid delivery is crucial for advancements in areas such as functional genomics and the development of cell and gene therapies. There has been a notable transition from non-viral chemical reagents to optimized electroporation systems and viral vectors, as efficiency and scalability become paramount. Additionally, a growing prevalence of cell and gene therapies, like CAR-T, heightens the need for robust transfection methods, prompting suppliers to enhance their offerings. AI is transforming this landscape by optimizing design and workflows, creating integrated solutions that enhance reproducibility, decrease development time, and stimulate partnerships in biopharma and biotechnology ecosystems.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Transfection market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell Transfection Market Segments Analysis

Global cell transfection market is segmented by transfection methods, end users and region. Based on transfection methods, the market is segmented into Electroporation, Lipofection, Calcium Phosphate, Viral Transfection and Others. Based on end users, the market is segmented into Academic Institutes, Pharmaceutical Companies, Biotechnology Companies and Contract Research Organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cell Transfection Market

The growth in research dedicated to gene therapies and nucleic acid-based medicines has significantly fueled the demand for effective cell transfection solutions. Researchers require dependable methods to deliver genetic material into various cell types for their discovery and preclinical development efforts. This scientific emphasis drives laboratories and contract research organizations to invest in validated transfection reagents and platforms that facilitate complex workflows. In response, suppliers are expanding their product offerings and enhancing performance characteristics. As a result, ongoing research endeavors stimulate innovation and commercialization within the transfection sector, strengthening supply chains and improving competitive options in the market.

Restraints in the Global Cell Transfection Market

The Global Cell Transfection market faces significant constraints due to high and variable costs associated with premium transfection reagents, specialized delivery systems, and automation platforms. These financial barriers particularly impact academic laboratories and smaller service providers, hindering their ability to procure necessary materials and limiting market penetration. Budget constraints often force researchers to favor established techniques over newer, pricier innovations, which can stifle demand for cutting-edge products. Additionally, cost sensitivity restricts necessary investment in the validation and optimization of methods needed for routine application, ultimately diminishing commercial adoption and discouraging suppliers from expanding their product ranges or exploring niche opportunities.

Market Trends of the Global Cell Transfection Market

The global cell transfection market is experiencing a significant upward trajectory driven by the increasing demand for precise and low-toxicity delivery methods in single cell applications. Researchers are focusing on advanced transfection techniques that maintain cell viability while facilitating robust expression essential for downstream omics workflows. This trend is prompting the development of scalable and gentle technologies compatible with microfluidic platforms, enhancing integration with single cell sequencing and high content analysis. As vendors prioritize reproducibility and ease of integration, cell transfection is emerging as a critical enabler for discovery, biomarker identification, therapeutic development, and clinical applications across various sectors.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Cell Transfection Market Size by Transfection Methods & CAGR (2026-2033)

• Market Overview
• Electroporation
• Lipofection
• Calcium Phosphate
• Viral Transfection
• Others

Global Cell Transfection Market Size by End Users & CAGR (2026-2033)

• Market Overview
• Academic Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations

Global Cell Transfection Market Size & CAGR (2026-2033)

• North America (Transfection Methods, End Users)
  • US
  • Canada
• Europe (Transfection Methods, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Transfection Methods, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Transfection Methods, End Users)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Transfection Methods, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Thermo Fisher Scientific, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promega Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OriGene Technologies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MaxCyte, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• POLYPLUS TRANSFECTION
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Biotech Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ATCC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellink
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EMD Millipore
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SignaGen Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mirus Bio LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• New England Biolabs, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellecta, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations